{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:44:52Z","timestamp":1787838292797,"version":"build-2784847793"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1213\/ane.0000000000000218","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T07:24:00Z","timestamp":1397114640000},"page":"16-25","source":"Crossref","is-referenced-by-count":14,"title":["A Novel Blood-Sparing Agent in Cardiac Surgery? First In-Patient Experience with the Synthetic Serine Protease Inhibitor MDCO-2010"],"prefix":"10.1213","volume":"119","author":[{"given":"Lars","family":"Englberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulf","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balthasar","family":"Eberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Erdoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Carrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210902","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1097\/01.CCM.0000217920.48559.D8","article-title":"Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting.","volume":"34","author":"Koch","year":"2006","journal-title":"Crit Care Med"},{"key":"R2-6-20210902","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1161\/CIRCULATIONAHA.107.698977","article-title":"Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery.","volume":"116","author":"Murphy","year":"2007","journal-title":"Circulation"},{"key":"R4-6-20210902","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.athoracsur.2006.06.072","article-title":"Thrombin during cardiopulmonary bypass.","volume":"82","author":"Edmunds","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"R5-6-20210902","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1213\/ANE.0b013e3181fc6df0","article-title":"Enhanced thrombin generation after cardiopulmonary bypass surgery.","volume":"112","author":"Lison","year":"2011","journal-title":"Anesth Analg"},{"key":"R7-6-20210902","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.athoracsur.2011.07.085","article-title":"High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.","volume":"93","author":"Kalavrouziotis","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"R8-6-20210902","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/cc9216","article-title":"Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis.","volume":"14","author":"Sander","year":"2010","journal-title":"Crit Care"},{"key":"R9-6-20210902","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1213\/ANE.0b013e3181c92b23","article-title":"High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.","volume":"110","author":"Murkin","year":"2010","journal-title":"Anesth Analg"},{"key":"R10-6-20210902","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1213\/ANE.0b013e3182354b7e","article-title":"Activation of the hemostatic system during cardiopulmonary bypass.","volume":"113","author":"Sniecinski","year":"2011","journal-title":"Anesth Analg"},{"key":"R11-6-20210902","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jtcvs.2009.10.059","article-title":"The novel synthetic serine protease inhibitor CU-2010 dose-dependently reduces postoperative blood loss and improves postischemic recovery after cardiac surgery in a canine model.","volume":"139","author":"Szabo","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R12-6-20210902","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/ALN.0b013e318191408c","article-title":"CU-2010-a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties.","volume":"110","author":"Dietrich","year":"2009","journal-title":"Anesthesiology"},{"key":"R14-6-20210902","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.athoracsur.2007.05.015","article-title":"Aprotinin and anaphylaxis: analysis of 12,403 exposures to aprotinin in cardiac surgery.","volume":"84","author":"Dietrich","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R16-6-20210902","doi-asserted-by":"crossref","first-page":"R16","DOI":"10.1186\/cc9960","article-title":"Clinical accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for acute kidney injury in patients undergoing cardiac surgery.","volume":"15","author":"Englberger","year":"2011","journal-title":"Crit Care"},{"key":"R17-6-20210902","doi-asserted-by":"crossref","first-page":"e3054","DOI":"10.1136\/bmj.e3054","article-title":"Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.","volume":"344","author":"Ker","year":"2012","journal-title":"BMJ"},{"key":"R18-6-20210902","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.athoracsur.2005.05.085","article-title":"Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.","volume":"81","author":"Poston","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"R19-6-20210902","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0003-4975(01)02821-1","article-title":"The antithrombotic and anti-inflammatory mechanisms of action of aprotinin.","volume":"72","author":"Landis","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"R21-6-20210902","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/bja\/aes310","article-title":"Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome.","volume":"110","author":"Koster","year":"2013","journal-title":"Br J Anaesth"},{"key":"R22-6-20210902","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0022-5223(19)35496-0","article-title":"Increased anticoagulation during cardiopulmonary bypass by aprotinin.","volume":"100","author":"de Smet","year":"1990","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R23-6-20210902","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-5223(19)34860-3","article-title":"Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass.","volume":"104","author":"Hunt","year":"1992","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R24-6-20210902","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1213\/ane.0b013e318182252b","article-title":"Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.","volume":"107","author":"Dietrich","year":"2008","journal-title":"Anesth Analg"},{"key":"R25-6-20210902","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1213\/ANE.0b013e3182576a5a","article-title":"The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.","volume":"115","author":"Kim","year":"2012","journal-title":"Anesth Analg"},{"key":"R27-6-20210902","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0022-5223(98)00431-0","article-title":"Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.","volume":"116","author":"Alderman","year":"1998","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000000218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:22:39Z","timestamp":1786112559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-201407000-00006"}},"subtitle":["A Phase II, Randomized, Double-Blind, Placebo-Controlled Study in Patients Undergoing Coronary Artery Bypass Grafting with Cardiopulmonary Bypass"],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000000218","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}